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ELECTRICAL STIMULATION AND GLUTAMATE IN THE HIPPOCAMPUS OF EPILEPSY
PATIENTS.
Gabriel A. Widi.

(Sponsored by Idil Cavus.)

Departments of Neurosurgery and Psychiatry, Yale

University School of Medicine, New Haven, CT.
Electrical brain stimulation has been proposed as a promising treatment option for patients with
medically resistant epilepsy disorder. Glutamate levels in the epileptogenic human hippocampus are
elevated interictally and increase with seizures. Fifty Hz stimulation is a candidate therapeutic stimulation
that is also used for clinical cortical mapping. We examined the effects of 50 Hz stimulation on glutamate
efflux in the hippocampus of patients with medically refractory epilepsy. Subjects (n = 10) underwent
intracranial EEG (icEEG) evaluation for possible therapeutic resection.

Electrical stimulation was

delivered through implanted hippocampal electrodes (n = 11) and microdialysate samples were collected
every 2 mins.

Basal interictal glutamate was measured with the zero-flow microdialysis method.

Stimulation of the epileptogenic hippocampus induced significant glutamate efflux at the time of
stimulation (p = 0.005, n = 10) that was significantly related to the basal glutamate concentration (R2 =
0.81, p = 0.001). During stimulation, four patients experienced seizures and two had auras. No change in
glutamate level was observed in the group of patients who experienced a seizure (p = 0.47, n = 4).
Conversely, a significant increase in glutamate was observed in the patients that did not experience a
seizure (p = 0.005, n = 7). Basal glutamate levels were significantly higher in the no seizure group (p =
0.04, n = 5) than in the stimulated seizure group (n = 4). Fifty Hz stimulation of the epileptogenic
hippocampus can cause significant glutamate efflux and may produce seizures or auras. The degree of
stimulated glutamate elevation is related to the basal glutamate concentration but not to the induction of
seizures.

Electrical stimulation at 50 Hz may exacerbate interictal glutamate dysregulation in the

epileptiogenic hippocampus and may not be optimal for seizure control.
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Introduction
Medication Resistant Temporal Lobe Epilepsy
Epilepsy is a common disorder affecting approximately 15 per 1000 people, causing a significant
amount of morbidity and mortality [1]. Medial temporal lobe epilepsy (MTLE) is the most common form
of epilepsy affecting about 2.5 million persons in the United States with a worldwide incidence of 4.87.8/1000 [2]. In about 40% of patients with TLE the seizures are medically intractable [3]. The disease is
characterized by partial seizures, which may or may not be secondarily generalized. Seizure activity in
MTLE involves a medial temporal lobe/limbic network [4]. Included in this network are the hippocampus,
amygdala, entorhinal cortex, lateral temporal neocortex, medial thalamus, and inferior frontal lobes [4].
The underlying pathology of MTLE is most often mesial temporal sclerosis (MTS), which is defined by
hippocampal neuronal loss and gliosis [5]. Patients with MTLE are refractory to anti-epileptic drugs
(AEDs) in about 75% of cases [5] and may continue to have disabling seizures or medication-related side
effects such as nausea, drowsiness, and weight gain [6]. Resective surgery is considered when such
seizures have a focal origin, and when presurgical evaluation clearly demonstrates that the epileptogenic
zone, i.e. the volume of brain tissue at the root of the generation of seizures, can be removed without
causing additional, unacceptable neurological or cognitive deficits. Although anterior temporal lobectomy
in persons with MTS can achieve one- to two-year remission in less than 85% of cases, resection of a welldefined neocortical lesion achieves one-year remission in only 56% [7]. Three to four year follow up after
neocortical or medial temporal lobe resection demonstrates cumulative relapse rates up to 25%, though
whether these relapses occur more often after medial temporal lobe resections has not been shown
consistently [8-12]. Depending on the localization of the seizure onset zone, conventional resective surgery
is unsuitable in at least one third of medically refractory patients because of the involvement of memory,
language, visual, sensory, or motor cortices, or because of the multifocal, bilateral or generalized
expression of the seizure disorder. Furthermore, surgical resection is not advisable in patients with bilateral
temporal foci of seizure spread or a unilateral focus of seizure origin spreading to surrounding cerebral
regions of the dominant hemisphere, because both bilateral conventional and unilateral extensive temporal
lobectomies can produce devastating cognitive deficits of language and memory.

Pharmacological
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advances are unlikely to decrease the number of such drug-resistant epileptic patients in the near future
[13], thus creating a need for better alternatives to AEDs and surgery.
Vagus nerve stimulation (VNS) as an adjunct to medical therapy is a reasonable option for patients
with refractory epilepsy who are not suitable for surgical resection and can result in a 50% reduction in
seizure frequency [14]. Nevertheless, most of these patients will not be seizure-free. In the controlled
trials leading to market approval, adults with partial onset seizures treated with optimal VNS stimulation
parameters had a median seizure reduction of 25–30%, and < 2% experienced seizure freedom at one year
[15]. Given the limitations of currently available therapeutic options, new approaches for treating epilepsy
are necessary. Due to the remarkable success of deep brain stimulation (DBS) for movement disorders [16,
17], combined with its advantages of titratability, reversibility, and low risk of complications [18, 19],
research into implantable deep brain devices for treating refractory epilepsy has increased tremendously
[20, 21].

Brain Stimulation Offers A New Therapeutic Option
Electrical stimulation of the human nervous system has been used successfully for diagnostic and
therapeutic purposes in a variety of neurologic diseases. Low-frequency stimulation of the spinal cord [22]
or of the thalamus [23] for the treatment of pain has proven beneficial. DBS is now a substitute for the
ablative lesioning methods used in stereotactic and functional neurosurgery for the treatment of movement
disorders and offers a reversible and adjustable intervention in all places where permanent ablative lesion
of neuronal structures, such as nuclei of the basal ganglia, had proven some therapeutic efficiency [24].
DBS was first applied to the thalamus to mimic thalamotomy for the treatment of tremor, then to the
subthalamic nucleus (STN) and the pallidum to treat the tremor, akinesia, rigidity and dyskinesias
associated with advanced forms of Parkinson’s disease [25]. The number of syndromes treated with DBS
is growing, and now includes depression [26, 27], dystonias [28], epilepsy [29-31], obsessive compulsive
disease [32], cluster headaches [33], and experimental approaches are being made in the field of obesity
and food intake control [34]. In epilepsy, the therapeutic effect of electrical stimulation have been variable,
and so far there is no consensus about where to stimulate and how [30]. Currently, there is a need to study
the effects of electrical stimulation on excitability in the epileptic brain to better inform and develop a
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rational stimulation paradigm. Different hypotheses have been proposed based on the clinical observation
that high frequency DBS may mimic ablative lesioning methods performed in stereotactic and functional
neurosurgery [35]. Stimulation-induced disruption of unopposed network activity is one hypothesis that
appears to be consistent with available data [36, 37]. DBS at high frequencies has also been postulated to
block cortical epileptiform activity [38-40]. How electrical stimulation affects neurotransmitter release in
the human adult brain is completely unknown.

Glutamate is a Primary Neurotransmitter and Neurotoxin
Glutamate is the major excitatory neurotransmitter in the brain and has long been implicated in the
initiation and spread of seizure activity [41]. In normal healthy brains, the extracellular concentration of
glutamate is kept within low safe levels by efficient reuptake mechanisms at a baseline level of one to two
micromolar (µM) [42]. Synaptic transmission increases glutamate transiently to one millimolar (mM),
activating postsynaptic glutamate receptors.

Primarily glial, and to some extent neuronal sodium-

dependent excitatory amino acid transporters (EAATs) then quickly and efficiently remove glutamate from
the synaptic cleft, returning its concentration to normal baseline levels [43]. In pathological conditions,
abnormal elevation of extracellular glutamate may result in neurotoxicity, cell death, and impaired function
[44]. The pathogenesis of glutamate-induced excitotoxic cell death occurs by way of an acute sodiumdependent phase followed by a delayed calcium-dependent phase [45]. The acute component occurs within
minutes of glutamate binding to the N-methyl-D-aspartic acid (NMDA) receptor. The overabundance of
glutamate hyperactivates the NMDA receptor, causing sodium influx associated with passive influx of
water and chloride with resultant neuronal dendritic swelling. The delayed component occurs hours postexposure and is triggered by excessive calcium influx, which produces a cascade-like effect leading to cell
death [45, 46]. This excessive calcium influx has been implicated in the glutamate-induced injury of
hippocampal neurons [47].
Animal studies have shown that the administration of glutamate or glutamate analogues to the
hippocampus triggers seizures, while co-injection of glutamate antagonists suppresses seizure generation
[48, 49]. A variety of established and potential antiepileptic drugs including phenobarbital, carbamazepine
[50], lamotrigine [51, 52], vigabatrin [52], diazepam [53], valproate and its derivatives [54], adenosine-1
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receptor agonists [55], kainate receptor antagonists [56], group I metabotropic glutamate receptor
antagonists [57], topiramate [58], angiotensin IV and somatostatin [59] suppress pilocarpine-induced
increases in hippocampal extracellular glutamate. Increases in hippocampal extracellular glutamate [60-69]
have been observed during different types of chemically and electrically induced seizures in rats. However,
others have found no change or even a decrease in hippocampal glutamate during seizures [70-74]. In a
microdialysis study by Sierra-Paredes and co-workers, intrahippocampal microperfusion of 100 μM
picrotoxin (a GABA-A receptor antagonist) over 5 min resulted in limbic seizures and a concomitant
decrease in hippocampal extraceullalr glutamate [75]. Conversely, Meurs and colleagues induced limbic
seizures of comparable severity by intrahippocampal microperfusion of picrotoxin, pilocarpine (a
muscarinic receptor agonist) and (R,S)-3,5-dihydroxyphenylglycine (DHPG) (a group I metabotropic
glutamate receptor agonist) in rats and observed increased extracelluar glutamate, GABA, and dopamine
following administration of convulsant in all groups [76]. Furthermore, they found that this increase was
related to seizure activity rather than to the pharmacological effects of the respective chemoconvulsants
[76]. Methodological differences between studies such as the duration of time between probe insertion and
start of dialysate collection or the duration of chemoconvulsant perfusion may give rise to contradictory
results even when the same sampling technique is used and should be taken into account when comparing
different studies of the effect of seizures on transmitter levels in the brain. In addition, regional differences
in seizure-related alterations in extracelluar glutamate and GABA concentration within the hippocampus
have been described [69], as well as different time courses of hippocampal extracellular glutamate and
GABA concentrations in maximal electroshock seizures in rats, with both increases and decreases at
different intervals [66]. Such spatial and temporal variations in the response of extracellular amino acid
levels to seizures within the hippocampus could account for some of the conflicting results of animal
studies. Currently, the seizure related increases in extracellular glutamate similar to those observed in
humans [67, 77] have been observed more reliably in chronic models of epilepsy, such as kindling with
electrical stimulation [78], or intrahippocampal [67] or amygdalar kainite acid (KA) injection [79].
Along the same lines, Wilson and colleagues report that the glutamate increase during seizures in
the human hippocampus is similar to the glutamate rise seen in the chronic kainate rat model of epilepsy
[67]. Elevated serum basal glutamate has also been noted in several familial epilepsies [80, 81]. Further,
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in vivo microdialysis studies of MTLE patients show that the extracellular concentration of glutamate rises
in the epileptogenic (and sclerotic) hippocampus, compared to the non-epileptogenic side, during
spontaneous seizures and remains elevated for at least 15 min after the electrographic seizure ends [77].
The regulation of glutamate in the epileptogenic human hippocampus appears impaired not only during
seizures but also during the interictal period, as the baseline extracellular glutamate is chronically elevated
[82], glutamate-glutamine cycling is decreased [83] and glutamate reuptake is possibly impaired [84-87].
Furthermore, this chronic elevation in glutamate may be linked to neurotoxicity, as we recently found that
higher glutamate levels in the epileptogenic hippocampus are related to decreased hippocampal volume on
MRI [88] and to increased neuronal cell loss [89]. Extracellular glutamate concentrations also increase
significantly in the epileptogenic hippocampus during the performance of complex figure memory tasks,
suggesting that the epileptic brain is particularly susceptible to the cognitive activation-induced glutamate
release [90]. Hippocampal sclerosis is also believed to play a key role in the generation of seizures in
MTLE [91, 92]. In the sclerotic hippocampus, changes in NMDA and AMPA receptors are observed [93,
94] and intracellular recordings from dentate granule cells in the human hippocampus reveal a glutamatedepedent hyperexcitability in these neurons [95]. As the above findings indicate, sclerotic hippocampi
seem to have an impaired glutamate uptake capacity in comparison to nonsclerotic hippocampi.
Previous groups [96, 97] have postulated a reduction in glutamate transporters to explain the
elevation of extracellular glutamate in the epileptogenic and sclerotic hippocampus [77, 82] during
seizures. However, other studies have offered little support for the role of glutamate transporters in this
phenomenon based on the expression of transporter proteins [98, 99].

On the other hand, Eid and

colleagues propose that astrocytic glutamate uptake may be influenced by changes in the metabolic state of
the glial cell rather than glutamate transporter protein levels.

Specifically, the down-regulation of

glutamine synthetase (an enzyme that converts glutamate to glutamine in an energy-dependent fashion) in
astrocytes in sclerotic areas of the hippocampus may lead to an accumulation of glutamate in involved
areas [98]. Given that glutamate transport in astrocytes is an active process, abnormal energy metabolism
could also be a contributory factor but little is known about the energetic state of sclerotic astrocytes to
support this hypothesis [100]. Another plausible explanation for the elevated glutamate levels in TLE with
sclerosis is that neuronal glutamate uptake may be impaired, though this idea is refuted by Peghini and
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colleagues [101]. In their study of EEAC1 (a neuronal glutamate transporter)-deficient mice (EAAC1−/−),
they showed that there is no neurodegeneration, apoptosis or reactive astroglia (an expected finding with
impaired glutamate clearance) even at greater than 12 months of age. These animals did not exhibit any
spontaneous epileptic activity nor did they exhibit a reduced threshold to pentamethylenetetrazole (PMT)
challenge [101]. Astrocyte-dependent glutamate release has also been postulated to explain the increased
levels of glutamate in sclerotic seizure foci [102]. Tian et al. provide evidence to support this hypothesis
by showing that in hippocampal slice models of seizure activity, calcium dependent glutamate release from
astrocytes rather than neuronal glutamate release predominantly underlies the paroxysmal depolarization
shifts that characterize seizure activity [102]. In human TLE, such calcium dependent glutamate release
from astrocytes could be triggered by inflammatory factors such as interleukin 1β and chemokines in
sclerotic hippocampi [91].

The Hippocampus is a Therapeutic Target for Brain Stimulation
The hippocampus is a structure often involved in seizure genesis [103] in TLE and is also often
selected as a stimulation target for the treatment of refractory epilepsy. Patients with complex partial
seizures (CPS) arising from the hippocampus who undergo resective surgery of the epileptic focus have a
positive outcome [8, 104-107], though relapse in patients with initially good results may occur. Most
seizure recurrences are within 6 months postoperatively [108], but many occur up to a decade later [109].
A review of studies with 1–5 year follow-up [7] reported freedom of disabling seizures in 63.% of patients
(95% CI = 60, 66) and identified a trend for better outcomes in more recent reports. Compared with Engel
et al., long-term follow-up studies (i.e. ≥5 years) of temporal lobe epilepsy surgery reveal a slightly lower
seizure free rate (median 58% in studies using author defined outcomes, and 65% in those using Engel's
class I “seizure free” classification) and a narrower range of seizure-free rates (59–89%) [110]. Thus, the
hope for seizure freedom following initially good results is tempered by the increasing risk of recurrence
over time. For a number of patients, surgical resection is not even an option. Temporal lobectomy or
hippocampectomy may cause memory deficits [111], or even amnesia [112], particularly in patients with
bilateral hippocampic surgery [113]. Instead, these patients are either excluded from resective procedures,
or surgery is performed under high risk with incomplete resections and residual seizures. The need for
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non-resective therapies is clear and has ushered in the use of neurostimulation for consideration in these
cases.
A number of anatomic targets have been stimulated, including the thalamic centromedian nucleus
(CMN) [114-116], vagus nerve [117-119], and cerebellum [120-122]. Stimulation of these targets has
improved secondary seizure generalization, but has shown variable results in patients with CPS.
Stimulation of the anterior nucleus of the thalamus (ANT) has been proposed [123]; however, preliminary
reports show significant, but limited effects on seizure control.

In these preliminary studies, basic

mechanisms underlying the beneficial therapeutic effect of hippocampal stimulation on seizures were also
investigated [124-127]. Velasco et al. report the case of a patient with intractable temporal lobe epilepsy
and normal MRI in whom depth-electrode recording showed bilateral independent hippocampal foci [125].
This patient received chronic bilateral hippocampal stimulation of biphasic 130 Hz pulses (450 μsec
duration, 400 μA) for 8 months, and this produced sustained seizure control without undesirable effects on
language and memory. Similarly, Vonck et al. (2002) report three CPS patients with DBS electrodes in the
amygdalo–hippocampal junction that received biphasic 130 Hz pulses as well, showing a 50–90% seizure
frequency decrease, while T´ellez-Zenteno’s group report a 15% seizure frequency reduction in four
patients with continuous monopolar stimulation of the hippocampus at 190 Hz [128, 129]. In another study
by Velasco et al. (2000), ten patients were transiently implanted with bilateral hippocampal or unilateral
subdural basal temporal electrodes before a planned temporal lobectomy. AEDs were discontinued from
48 h to 72 h before 2–3 weeks of continuous 130 Hz electrical stimulation, delivered 23 h per day [130]. In
seven patients with stimulation electrode in the hippocampal formation or parahippocampal gyrus who
experienced no interruption during the stimulations, clinical seizures stopped and the number of interictal
EEG spikes at the focus decreased after 5–6 days. No evident therapeutic response was found in three
patients when stimulation was either interrupted or given outside the hippocampus.
In most of these studies, electrical stimulation of the hippocampus was tried on a short-term basis
(<1 month) during preoperative intracranial EEG assessment. Emerging reports of chronic hippocampal
stimulation (3 to 6 months) demonstrate similar benefits to those documented with short-term stimulation,
without evidence of adverse effects [126, 128, 131]. However, most published studies include neither
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blinding nor controls. This is important because, with few exceptions, [122, 132] DBS studies that use
blinded assessments or controls report little or no effect of stimulation [133-135]. Also, reports of seizure
improvement following electrode implantation for intracranial EEG monitoring [136] raise the possibility
that implantation itself can confound stimulation studies.

Given these limitations, the only way to

determine the efficacy of hippocampal neurostimulation for seizure control is through randomized
controlled trials with blinded outcome assessment. One example is a recent double-blinded controlled
study by Velasco et al. that reported 5 of 9 patients demonstrated a significant decline in seizure occurrence
within 1-2 months of hippocampal stimulation at 130 Hz [132]. The remaining four patients exhibited a
delayed response, with only a slight decrease in seizure frequency evident after 6-8 months of hippocampal
stimulation. Although seizure reduction occurred in all patients, the observation was made that not all
MTLE patients respond in the same manner, as a difference between patients with normal MRIs and those
with hippocampal sclerosis was noted: the five responders to hippocampal stimulation had a normal MRI
while the four non-responders demonstrated hippocampal sclerosis. For patients with normal MRI, this
observation implies the possibility of having a non-lesional neurosurgical alternative, such as DBS, since it
has been reported that these patients have a less favorable outcome and a higher risk of memory
impairment after temporal lobectomy [111, 112]. In patients with hippocampal sclerosis, partial and
delayed response in seizure reduction could explain the limited results found in the T´ellez-Zenteno et al.
(2006) study because one inclusion criterion in this report was MRI-demonstrated hippocampal sclerosis.
In these patients, seizure reduction was partial and occurred after eight months of electrical stimulation.
Based on these observations, Velasco et al. speculate that in order to achieve a satisfactory response to
stimulation it is important that the neuronal network be preserved in the stimulated area [132]. They
support this hypothesis by reasoning that the severe neuronal reduction that accompanies MTS may
represent a less satisfactory tissue for modulation with stimulation [132]. This line of thought is supported
by a previous report from the same group [127] linking the response to subacute electrical stimulation with
high GABA levels in the stimulated tissue. GABA levels were significantly higher in specimens with
higher cell counts derived from patients with minimal or no MTS. Our research indicates that chronically
elevated glutamate levels linked to neuronal cell loss [89], may be an additional obstacle for treatment with
DBS. Another possibility is that sclerotic tissue has different conductance properties than normal tissue and
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may require stimulation at different charge density [132].
Suppression of hippocampal epileptiform activity by electrical stimulation has also been shown in
studies using in vivo and in vitro animal models and human hippocampal slices [137]. Low-frequency
stimulation (LFS) of the hippocampus can lead to long-term depression (LTD) in experimental animals,
and a possibly similar effect of low-frequency stimulation has been demonstrated in resected human
temporal lobe specimens [30]. On the other hand, high-frequency stimulation (HFS) might produce local
inhibition of the epileptogenic zone. Another possible explanation for the anti-seizure effect of HFS of the
hippocampus is that it is mediated through activation or inhibition of downstream structures, rather than the
stimulated region itself [128, 138]. Electrical stimulation of the hippocampus for therapeutic reasons in
patients with medically refractory epilepsy [125, 138] may also induce glutamate release [139], which has
the potential to exarcebate the excitotoxicity and epileptogenicity of the stimulated site [49, 85, 140, 141].
In rats, electrical stimulation of the hippocampus is reported to cause a rapid transient increase in glutamate
concentration and concomitant enhancement in synaptic efficacy [139].

Other studies indicate that

repeated increases in glutamate, whether by direct microinjection [142, 143] or by application of high
potassium [144], can increase seizure frequency and lead to a kindling-like state that may contribute to
further elevation in basal glutamate [79].

Thus, it is important to investigate if and how electrical

stimulation affects glutamate release in the human hippocampus.

Such information may elucidate

mechanisms underlying electrical stimulation in humans and may also provide insight into its effects on
seizure control, neuronal preservation and therefore the clinical outcome in these patients.

High Frequency Brain Stimulation for Seizure Control
Electrical brain stimulation at high frequencies (50 - 130 Hz) has been studied in a number of
human trials. Open label studies investigating high frequency stimulation (HFS) of the CMN [116, 125,
145-147], hippocampus [125, 126, 128-130, 132], STN [148, 149], ANT [123, 150-152], and cerebellar
dentate nucleus (CDN) [146] have shown promise; however, only one [122, 132] of these techniques have
been effective in blinded trials [153, 154]. Velasco et al. demonstrated in a double-blinded randomized
control study of hippocampal stimulation at 130 Hz in nine patients, that seizure frequency was
significantly decreased in five of nine patients with four of them remaining seizure free at 18 months of
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follow-up [132]. Other multicenter prospective randomized trials of scheduled (open-loop) chronic ANT
stimulation [154] and of intracranially implanted responsive (closed-loop) neurostimulation in persons with
medically intractable localization related epilepsy are now under way [154].
Brain stimulation at 50 Hz is a candidate method for seizure control [123, 155-157]. This form of
stimulation is used extensively for functional brain mapping of medically refractory epilepsy patients
evaluated for surgical resection. In clinical practice, subdural cortical stimulation with brief electrical
bursts at 50 Hz can disrupt or induce the relevant behavior and in some cases, if the epileptogenic site is
stimulated directly, may trigger seizure. Systematic studies in a limited number of refractory epilepsy
patients have reported that subdural cortical stimulation at 50 Hz may suppress epileptic activity at the site
of stimulation. Kinoshita et al. showed in an open label study that 50 Hz (bipolar, biphasic square wave
pulses of 0.3 ms duration 1-15mA for 5 s) stimulation of epileptic cortex in four patients with medically
intractable focal epilepsy suppressed interictal spikes and reduced EEG power at the site of stimulation
[157, 158]. Moreover, they showed that 50 Hz stimulation of both epileptic and non-epileptic areas
suppressed electrographic fast activities in the stimulated area, confirming previous observations [158,
159]. These findings are in concordance with previous studies showing the suppression of afterdischarges
(ADs) by brief bursts of responsive cortical stimulation at 50 Hz. (biphasic 0.3 s, 50 Hz pulse presented for
0.3–2 s) of subdural electrodes during functional brain mapping in patients with medically resistant
epilepsy [155, 156].
Fifty Hz stimulation has also been shown to decrease epileptic activity in vivo and in vitro animal
models of epilepsy. Bikson et al. found that sinusoidal high frequency electric fields at 20-50 Hz (144 ± 36
mV) induced across the CA1 and CA3 regions in rat hippocampal slices suppressed zero-calcium, lowcalcium, picrotoxin, and high potassium epileptiform activity for the duration of the stimulus and for up to
several minutes following the stimulus by inducing potassium efflux and depolarization block [160].
Durand and colleagues replicated these findings using 50 Hz sinusoidal stimulation of the CA1 region of
the rat hippocampus and added that 50 Hz stimulation to the alveus suppressed both the evoked potentials
in the cell bodies of neurons and the compound action potentials from their axons [161]. These findings
could not be attributed to desynchronization or damage and were associated with increased extracellular
potassium concentrations. Instead, their data give insight into the effects of 50 Hz stimulation on neuronal
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elements and how stimulation can block axonal activity through non-synaptic mechanisms. Similarly, 50
Hz stimulation (biphasic square wave pulses lasting 0.2–0.4 ms) of rat neocortical slices treated with either
bicuculline or magnesium-free extracellular solution prematurely terminated ~50% of seizure-like events
[162]. In addition, partial pharmacological blockade of ionotropic glutamate receptors was sufficient to
suppress epileptiform discharges and enhance the antiepileptic effects of 50 Hz stimulation, suggesting that
the antiepileptic effects of stimulation were mediated mostly by short-term synaptic depression of
excitatory neurotransmission [162]. Several other in vitro and in vivo animal studies investigating similar
HFS from 100-130 Hz in the rat hippocampus [163], STN [36, 40, 164], mammilary nuclei [165],
substantia nigra pars reticulata (SNr) [166, 167], and ANT [168-170] have also shown decreased seizure
activity.

How High Frequency Brain Stimulation Affects Neurotransmitter Release is Largely Unknown
Our knowledge of how 50 Hz electrical stimulation affects neurotransmitter efflux in an in vitro or
in vivo model for epilepsy is minimal. Klancnik et al. stimulated Schaffer collateral-commisural fibers
from the rat hippocampus continuously at 50 Hz (mean 230 µA, 100 µs square pulse width) for four
minutes, inducing the tetrodotoxin-sensitive release of aspartate, glycine, cysteine sulphinic acid, and
homocysteic acid, supporting the role for these endogenous amino acids in synaptic transmission in the
hippocampus [171]. Ghijsen and colleagues [172] reported that 50 Hz stimulation (300 μA, biphasic
stimuli, 200 μs2 pulse width of 3-s duration applied at 20-s intervals during a 4-min period) of hippocampal
slices in a rat kindling model achieved by daily titanic stimulation of the Schaffer-collateral fibers showed
transient increase in GABA in the presence of a GABA receptor blocker.

Since similar studies

investigating neurotransmitter efflux in response to 50 Hz and other similar HFS do not exist, we must look
to the movement disorder literature to further our understanding. Mantovani et al. showed that HFS at 130
Hz on human neocortical slices induced increased GABAergic activity, confirming earlier findings in the
rat caudate-putamen [173-175]. Meanwhile, an in vivo model developed by Hiller et al. showed that HFS
at 124 Hz significantly increased basal GABA outflow from the CN of freely moving rats without affecting
glutamate levels [176]. HFS (130 Hz) has also been shown to induce glutamate release in the rat globus
pallidus (GP) and SNr as well as GABA release in the SNr [177]. On the other hand, Iremonger et al.
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studied HFS in the rat primary motor cortex and ventro-lateral thalamus and contend that HFS (125-185
Hz) of the subcortical white matter tracts projecting to the rat motor cortex caused depression of excitatory
synaptic currents in postsynaptic neurons through neurotransmitter depletion [178].

Microdialysis for Glutamate Levels in the Epileptogenic Hippocampus
Maintenance and regulation of the composition of the brain extracellular fluid is critical for normal
neuronal transmission. Through the use of microdialysis, we can explore the in vivo neurochemistry of the
conscious human brain by continuously sampling ECF for extended periods of time. The microdialysis
method is widely used in animal models of disease, including epilepsy, movement disorders, ischemia,
trauma, subarachnoid hemorrhage and so forth, to measure for drug levels, neurotoxins, and
neurotransmitters in the ECF. Clinical applications for microdialysis in humans include the monitoring
and/or study of brain neurochemistry in relation to trauma, ischemia and hemorrhage during neurointensive
care, in brain tumors in the neurosurgical setting, and in intracranial EEG monitoring for epilepsy patients
to identify a seizure focus [179, 180]. In patients undergoing presurgical evaluation with intracranial EEG,
microdialysis catheters are implanted into the area of interest so that ECF may be sampled and analyzed for
composition and concentrations of neurotransmitters [67, 77]. Chemicals in the brain ECF diffuse down a
concentration gradient across a semi-permeable membrane into the perfusion fluid inside the catheter,
which is collected for analysis. As the perfusing fluid passes through the dialysis probe, the concentration
gradient generated between the regional brain ECF and the intraluminal fluid drives molecules smaller then
the molecular cut-off of the membrane into the probe. The amount of brain chemical recovered through the
outlet represents a fraction of its actual concentration. The efficiency of recovery depends on factors such
as the molecular weight, charge, uptake and metabolism of the measured compound, diffusion, tortuosity
factors in the interstitial microenvironment, length and composition of the dialysis membrane, flow rate,
temperature and composition of the perfusion fluid. Usually, higher relative recovery is obtained at lower
perfusion rates and with longer membranes. The collected dialysate can be either frozen at – 80°C for
future analysis or analyzed on-line using HPLC, capillary electrophoresis, mass spectroscopy or enzymebased methodologies. The microdialysis probe can be combined to the depth electrodes for simultaneous
electrophysiological recording. Microdialysis typically samples neurochemical changes related to volume
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transmission in the extrasynaptic space and only indirectly provides information on changes within the
synapse [181-183]. The extrasynaptic concentration of a transmitter reflects a balance between its rates of
neuronal and glial (vesicular and non-vesicular) release and reuptake. The extracellular levels may also
reflect extrasynaptic spillover or transmitters that may have escaped uptake and degradation by the synapse.
As such, measured ambient neurotransmitter levels may be most relevant for the volume transmission and
function of the extrasynaptic receptors [184].

Microdialysis catheters have also been employed

concurrently with bilateral depth electrode placement in the mesial temporal lobe of conscious epileptic
patients prior to resective surgery [67, 77, 185] to show extracellular glutamate surges in the epileptogenic
hippocampus at the onset of clinically observed seizures.
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Statement of Purpose
In this study, we used microdialysis probes coupled to hippocampal depth electrodes to investigate
the effect of 50 Hz electrical stimulation on glutamate release in refractory epilepsy patients. In brief, we
used 50 Hz stimulation because this frequency is employed extensively and with relative safety for
functional brain mapping of epilepsy patients evaluated for surgical resection. In clinical practice, subdural
cortical electrode stimulation with brief bursts of electrical pulses at 50 Hz can disrupt or induce sitespecific behavior and, in some cases, if the epileptogenic zone is stimulated directly, trigger seizures.
Cortical stimulation at 50 Hz has also been proposed as a candidate method for seizure control, as it
suppresses stimulus-induced ADs [155, 156], interictal spike frequency and EEG power in the epileptic
cortex of refractory epilepsy patients [157-159]. Moreover, studies in rat brain slices have suggested that
stimulation at 50 Hz can suppress epileptiform activity through various mechanisms, including
depolarization block [160], short-term excitatory synaptic depression [162], and increase in GABA release
[172]. Our previous work indicates that extracellular glutamate in the epileptogenic hippocampus is
chronically elevated, suggesting that glutamate regulation is impaired [82].

We hypothesized that

stimulation would induce further changes in glutamate at these sites. Therefore, we investigated the
relationship between basal glutamate, as measured with quantitative zero-flow intracranial microdialysis,
and stimulus-induced glutamate efflux.
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Methods
Subjects
Subjects were patients with medication-resistant CPS undergoing phased clinical evaluation for
possible resective surgical treatment. In Phase I, patients are admitted to a hospital-based epilepsy unit for
continuous audio-video and scalp electroencephalogram (EEG) monitoring to record interictal epileptiform
transients and ictal patterns during at least three typical seizures. Patients have brain magnetic resonance
imaging (MRI) interictal and ictal single-photon emission computed tomography (SPECT), interictal
positron emission tomography (PET), and extensive neuropsychological assessment. Phase II evaluation
consists of the intracarotid amobarbital procedure to determine lateralized memory function and
hemispheric dominance for language. Those patients in whom the seizure focus is not localized by Phase I
evaluation, or if there was discordant findings, are offered intracranial EEG monitoring (icEEG) (Phase III
study). This phase of the evaluation involves continuous audiovisual monitoring and EEG recording from a
combination of depth, subdural strip, and grid electrodes implanted intracranially to target brain regions
suspected of being involved in seizure generation or propagation. Patients undergoing Phase III evaluation
were invited to participate in the microdialysis study between 2000 and now. Patients who consented to
participate in the microdialysis and electrical stimulation studies approved by the Yale University School of
Medicine Human Investigations Committee were stereotaxically implanted with microdialysis probes with
combined depth electrodes targeting the suspected epileptic hippocampus. icEEG Recordings from the two
depth electrode contacts flanking the microdialysis membrane were used to determine whether the
microdialysis catheter was within or outside an epileptogenic area. The epileptogenic area was defined as
the site of seizure origin in at least one seizure, whereas the non-epileptogenic sites were either not
involved or were only secondarily involved (propagated) during seizures.
Ten patients selected randomly (four male and six female, age 34.75 ± 13.63, mean ± SD, see
Table 1) with eleven hippocampal probes were stimulated at 50 Hz per protocol. Nine patients had one
hippocampal probe stimulated, while one subject had two ipsilateral hippocampal probes stimulated. Two
patients with probes that were not accurately placed in the hippocampus or with probes near tumor or
dysplasias were excluded. The demographic information of participating patients was obtained by medical
chart review and then recorded in a common database. Table 1 summarizes patient information regarding
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gender, duration of epilepsy, probe location, and classification of disease state as epileptogenic versus nonepileptogenic of patients included in the final analysis. MRI findings of the hippocampus ipsilateral to the
probe are reported, as well as pathology at the probe site following resection if available. The data
represented in Table 1 were collected by M. Cassaday, D. Ocame, and S. Forselius and myself.

Table 1. Subject characteristics. Data was collected from 10 subjects implanted with 11 probes (*subject
#3 had two probes stimulated).
Probe
Placement

Disease

Stimulated
Sx

Clinical MRI

AEDs

49

Epilepsy
Duration
(yrs)
24

L Hipp

Epi

Sz

Normal

LEV

M

23

23

R Hipp

Epi

Sz

Normal

3*

M

47

26

Epi

4

M

17

7

L Ant Hipp
L Post Hipp
R Post Hipp

Epi

Aura
Sz
Aura

5

F

52

17

R Ant Hipp

Epi

None

6

F

17

8

L Hipp

Epi

None

7

M

40

23

L Hipp

Epi

None

L Hipp
Atrophy
R Hipp
Atrophy
BL Hipp
Atrophy
L Hipp
Atrophy
L Hipp
Atrophy

DPH,
TPM
TPM

8

F

38

36

Epi

None

9

F

43

20

R Ant Hipp^ R
Post Hipp
L Hipp

Epi

None

R Hipp
Atrophy
Normal

10

F

24

12

R Hipp

Nonepi**

Sz

Normal

Pt

Sex

Age
(yrs)

1

F

2

Abbreviations: AEDs, anti-epileptic drugs; Ant, anterior; Epi, epileptogenic; Hipp, hippocampus; L, left;
Non-epi, non-epileptogenic; Post, posterior; R, right; Sx,; symptoms; Sz, seizure; Yrs, years. AED
abbreviations: CBZ carbamazepine; CLZ clonazepam; DPH phenytoin; GBP gabapentin; LTG
lamotrigine; LEV levitiracetam; OXC oxcarbazepine; PB phenobarbital, TPM topiramate; ZNS
zonisamide. ^(Not Stimulated) ** focus in R Parietal cortex

CBZ,
DPH
DPH
LEV,
CBZ
LTG,
DPH,
TPM
PB
CBZ,
LTG
DPH

20
General Procedures
Microdialysis probes coupled to depth electrodes (Spencer probe; Ad-Tech Instrument, Racine,
WI) were implanted stereotaxically in the suspected epileptogenic hippocampus using a stereotactic
neuronavigation device (BrainLAB, Westchester, IL).

All surgeries were performed by Drs. Dennis

Spencer, Kenneth Vives, and members of the Yale-New Haven Hospital Department of Neurosurgery. The
design of the earlier Spencer probe has been modified [186]. Briefly, the probes are CMA/20 custommodified concentric and flexible microdialysis probes (0.67 mm diameter, 70 mm length, 10 mm
membrane with 20 kDa cut-off

CMA/20 (CMA, North Chelmsford, MA) which allow stable flow,

recovery, and dialysate collection for one-two weeks, and usually throughout the duration of intracranial
EEG monitoring. The dialysis probe is inserted into a polyurethane/silastic flexible depth-electrode (1 mm
i.d., Ad-Tech Instrument Co., Racine, WI), which has perforations between contacts 1 and 2 to allow for
fluid exchange with the membrane. The total diameter of this combination microdialysis/depth electrode
(Spencer probe) is 1.85 mm. The probes are sterilized by gamma radiation and flushed with sterile
artificial extracellular fluid (AECF) to ensure patency prior to insertion. Following surgery, threedimensional co-registered CT and MRI is used to verify probe location (See Figure 1. A-C). After one to
two days of recovery, patients are transferred to the epilepsy monitoring unit and the AEDs are tapered to
allow for spontaneous seizures. Patients usually undergo continuous audiovisual and icEEG monitoring
from one to two weeks. Once a satisfactory number of spontaneous habitual seizures are obtained, the
AEDs are reinitiated and all intracranial probes are removed. Whether the microdialysis membrane was in
the hippocampus of seizure origin (epileptogenic hippocampus) is determined based on the consensus
interpretation of the collected icEEG data by epileptologists experienced in intracranial electrophysiology
and confirmed by the long-term outcome of resective surgery..
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Figure 1. (A) Spencer depth electrode with inserted microdialysis catheter prior to intracranial
implantation. (B) Intraoperative implantation of depth electrodes with attached microdialysis catheters and
placement of subdural grid electrodes into the temporal cortex of a patient undergoing Phase III
evaluation. (C) Magnetic resonance image (MRI) from a patient with one Spencer probe implanted in the
right hippocampus. Depth electrode contacts 1 through 8 are visible (highlighted in red). The platinum
contacts of the depth electrode generate significant artifact and appear much larger than their actual
diameter of 1mm. The microdialysis membrane, which is not visible on magnetic resonance imaging, lies
between depth electrode contacts 1 and 2.
A
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B
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Zero-Flow Microdialysis
The zero-flow microdialysis method estimates the steady state or basal concentration of the
measured substrate in the extracellular fluid (ECF) [187], and has previously been described [82]. In brief,
the study was conducted two to five days after implantation, in the afternoon, when patients were quietly
resting, at least six hours from any intracranially recorded seizure activity, and 168 ± 81 hrs (mean ±
SDEV) before the stimulation study, to avoid the effects of acute probe implantation, anesthesia, ictal
activity, behavioral stimuli, or food intake [188-190]. Patients were on a combination of AEDs (Table 1).
Sterile artificial cerebrospinal fluid (composition: 135 mM NaCl, 3 mM KCl, 1 mM MgSO4*7H20, 1.2
mM CaCl2*2H20 in 1 mM sodium phosphate buffer, pH 7.4) was infused using portable CMA 107 syringe
pumps (CMA, North Chelmsford, MA) at a rate of 2.0 µl/min for one hour to reach steady state. Dialysis
samples (20 µl) were collected at progressively decreasing flow rates (2.0 – 1.5 – 0.5 and 0.2 µl/min),
allowing a period of 60 - 90 min for equilibration after each rate change. Chemical substrates in the
hippocampal interstitial fluid diffuse across the dialysis membrane into the artificial CSF within the probe,
which is then collected via the outlet tubing on the microdialysis probe into microvials. The experiment
was completed in approximately six hours. Samples were stored on dry ice and then at - 80°C for later
analysis of neurometabolite concentration using high-performance liquid chromatography (HPLC). The
basal levels at steady state (i.e. at 0.0 μl/min) were estimated using regression analysis to fit a second order
polynomial extrapolated to a flow of zero (i.e. x=0). The zero-flow studies for this set of patients were
collected by M. Cassaday, D. Ocame, S. Forselius, and G. Widi.

Electrical Brain Stimulation
To decrease the probability of stimulus-induced seizures, electrical stimulation was applied when
the clinical monitoring was completed and patients were restarted on their AEDs, usually on the day before
electrode removal. The two contacts (contacts 1 and 2) flanking the microdialysis probe on the tip of the
hippocampal depth electrode were stimulated in bipolar fashion using a Grass S12 constant current square
wave generator (Grass Instrument Division, Astro-Med Inc, West Warwick, RI). A series of single pulse
stimulations were used to determine the stimulation current for the 50 Hz stimulus train with a maximum
stimulation current defined as one that does not produce any afterdischarges or uncomfortable subjective
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sensations, up to 10 mA. After a 20 minute baseline period, three 50 Hz trains (biphasic square wave
pulses, 0.2 msec per phase) of 5 second duration were applied with 5 second interval (total pulse number
750). Microdialysate from stimulated hippocampal probes was collected using the CMA/170 microdialysis
fraction collector (CMA, North Chelmsford, MA) every 2 mins at a flow rate of 2.0 µl/min. The samples
were stored initially at -4 ˚C and then at -80 ˚C. The icEEG data from this group of patients was not
available for later analysis. R. Duckrow performed the electrical stimulation while G. Widi and D. Ocame
collected the microdialysis data.

High Performance Liquid Chromatography Analysis of Glutamate Levels
Microdialysate samples were analyzed for glutamate levels using the HPLC method modified
from the method previously described by Bourdelais and Lakivas [191]. In brief, 1 µl of patient sample is
added to 9 µl of an internal standard of alpha-aminoadipic acid (AAA). This mixture is derivatized by
adding 20 µl of an O-phthaldialdehyde. After eight minutes, 20 µl of the derivatized sample is injected
onto the column (3 µm Phase II ODS column, 3.2 x 100 mm cartridge, Bioanalytical Systems, Inc., West
Lafayette, IN). The mobile phase consists of 0.1M acetic acid (pH 6.0) with a 12 to 20% acetonitrile
gradient at a 1 ml/min flow rate. Within 30 minutes, chromatograms demonstrate adequate separation
showing glutamate approximately at 6.9 minutes and AAA at 7.7 minutes (see Figure 2). The excitation
and emission wavelengths on the florescence detector (Shimadzu Scientific Instruments, Columbia, MD)
are set at 338nm and 425nm, respectively. The sensitivity limit for glutamate is 0.1, based on a signal-tonoise ratio of 10:1. Peak areas of the neurometabolite on chromatograms are then compared with external
standards to determine the concentration in the samples using EZCHROME elite software from ESA
(Chelmsford, MA). HPLC analysis for this set of patients was kindly performed by M. Cassaday, D.
Ocame, and G. Widi.
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Figure 2. High-performance liquid chromatogram sample showing the peak separations for aspartate
(asp, 2.0µM), glutamate (glu, 1.7µM), the internal standard α-aminoadipic acid (AAA), and glutamine (gln,
80.5µM). (Reprinted with permission from Cavus et al, Annal Neurol 2005.)
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Statistical Analysis
The timing of microdialysate samples from the stimulation study was corrected for dead volume
(14 mins at 2 µl/min). The change in glutamate concentration in response to the stimulation was expressed
as % change from baseline and was analyzed using repeated measures ANOVA and Tukey-Kramer’s posthoc test (SAS statistical program, version 5, SAS Institute, Cary, NC). Since basal glutamate data was not
normally distributed, log transformation was used to achieve normality.

Linear regression on log-

transformed data was used to analyze the relationship between basal interictal glutamate levels and the peak
glutamate level at the time of stimulation. In addition, to increase the confidence in our statistical model, a
non-parametric test (Spearman’s rank correlation test) was used to correlate the raw basal glutamate levels
to the raw post-stimulus glutamate levels. The significance level was set at 0.05 and all data are reported as
mean ± standard error of the mean (SE). This investigator organized the dataset, and performed all
statistical analyses in conjunction with I. Cavus.
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Results
In nine out of ten cases, the hippocampus studied with electrical stimulation was either the site of
seizure genesis or propagation (epileptogenic hippocampus). Of those nine probes in the epileptogenic
hippocampus, six were placed within an atrophic hippocampus and three were within a normal-appearing
hippocampus, as determined by the clinical MRI interpretation (Table 1). The epileptogenic hippocampus
was resected in six cases, and spared in three cases to avoid functional impairment (Table 2). From the six
resected hippocampi, three showed minimal cell loss and three showed sclerosis on subsequent
hispathological examination. The three cases that showed sclerosis also had marked atrophy on MRI, while
the three cases that showed minimal cell loss were normal on MRI. Of patients with hippocampal
resection, three were seizure-free and three had a significant decrease in seizures at one-year post-operative
follow-up (Table 2). In patient number 10, seizures originated from parietal cortex and did not involve the
hippocampus (non-epileptogenic hippocampus).

Table 2. Seizure localization, surgery, pathology, and follow-up at one year post-operatively.

Min cell loss
Min cell loss
N/A

Sz Freq Pre-Op
(per month)
10
2
8

Total Sz at 1 Yr
Follow-Up
4
None
1

Sclerosis
Sclerosis
N/A
Sclerosis
N/A

13
3
7
12
8

4
2
N/A
None
None

Min cell loss
N/A

30
40

None
None

Pt

Localization

Resection

Hipp Pathology

1
2
3

L Hipp
R Hipp
Multifocal

4
5
6
7
8

R Med Hipp
R Post Hipp
L Ent Ctx
L Ent Ctx
Post temp ctx

9
10

L Ent Ctx
R Par Neoctx

L AMTL
R AMTL
None – VNS
offered
R AMTL
R AMTL
None*
L AMTL
R post temp
neoctx
L AMTL
R lat tempoccip

Abbreviations: AMTL, Anterior medial temporal lobectomy; BL, bilateral; Ent Ctx, entorhinal ctx; Freq,
frequency; Hipp, hippocampus; lat, lateral; L, left; med, medial; min, minimal; N/A, Not Applicable;
Neoctx, neocortex; Par, parietal; post, posterior; prop, propagated; occip, occipital lobe; R, right; temp,
temporal cortex; Sz, seizure; Yr, year. * - Resection not performed because of risk of memory impairment VNS offered instead.

28
50 Hz Stimulation of the Human Epileptogenic Hippocampus Induces Glutamate Efflux
Stimulation at 50 Hz (stimulation strength 6 - 10 mA) caused an increase in glutamate efflux in the
epileptogenic hippocampus (F (16,143) = 2.338, p = 0.005, n = 10, Figure 3). This increase was significant
only at the time of stimulation (p < 0.05, Tukey’s post-hoc test), when it reached 390 ± 115% of baseline
and then declined to pre-stimulation levels within the next few minutes. In six patients, the glutamate
levels were elevated two-fold over baseline for 4 minutes following stimulation. However, the analysis of
the group data showed significant elevation only at the time of stimulation. In one patient (patient #10),
stimulation of the non-epileptiogenic hippocampus triggered a brief habitual seizure, but had no discernable
effect on glutamate efflux (data not shown). In another patient (patient #8) with probes in the ipsilateral
anterior and posterior hippocampus, stimulation of the posterior hippocampus did not cause change in
glutamate levels at the anterior probe indicating that the effect of stimulation on glutamate efflux in the
posterior-anterior axis of the hippocampus can be local. The distance between these two probes was
approximately 14.1 mm (Figure 4A). As seen in Figure 4B, the 50 Hz stimulation induced glutamate efflux
30 times greater than baseline only at the stimulated posterior probe site, with no change in the nearby
anterior hippocampal probe. Although glutamate efflux in the sclerotic hippocampus (250 ± 188%, n = 3)
was greater than the hippocampus exhibiting minimal cell loss (206% ± 88%, n = 3), this difference was
not significant (p = 0.733), possibly due to the small number under analysis.
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Figure 3. Fifty Hz electrical stimulation (at 0 min) of the epileptogenic hippocampus induced significant
glutamate efflux at the time of stimulation compared to baseline (*p < 0.05, n = 10, Tukey’s post-hoc test).
Microdialysis samples were collected every two minutes at 2 μl/min flow rate from 10 patients.
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Figure 4. (A) MRI image of a patient who had two ipsilateral probes implanted in the right anterior and
posterior hippocampus. The two probes were 14.1 mm apart and were both classified as epileptogenic with
the seizure onset site in the right posterior temporal lobe. Only the posterior probe was stimulated. (B)
Simultaneous microdialysis from the anterior (not stimulated) and posterior (stimulated) hippocampus
probes shows that the stimulus-induced glutamate release is limited to the stimulated probe. Abbreviations:
Ant-Anterior, Hipp-Hippocampus, Post-Posterior, R-Right, Stim-Stimulated, and Temp-Temporal.
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Higher Basal Glutamate Levels are Related to Higher Stimulated Increase in Glutamate:
We have previously reported that basal interictal extracellular glutamate concentration in the
epileptogenic hippocampus are abnormally elevated [82]. Hypothesizing that the interictal impairment in
glutamate regulation underlies its increase with stimulation, we examined the relationship between basal
levels and peak glutamate at the time of stimulation.

Basal (zero flow) glutamate levels in the

epileptiogenic hippocampus ranged from 1.67 to 17.46 μM (6.56 ± 5.68, mean ± SDEV, n = 8, basal levels
were not obtained for two probes), and in the non-epileptiogenic hippocampus of one patient glutamate was
1.40 μM, consistent with values reported earlier [82].
Linear regression analysis on log-transformed data showed that higher peak glutamate levels at the
time of stimulation were significantly related to elevated basal glutamate levels (R2 = 0.81, p = 0.001,
Figure 5). A non-parametric test on raw data revealed an even stronger correlation (R = 0.90, p < 0.0009,
Spearman’s test). Thus, the higher the basal interictal levels in the hippocampus, the higher the glutamate
peak is in response to 50 Hz stimulation, with 80 – 90 % variability in the stimulus-related glutamate
increase being due to the degree of elevation in basal glutamate.
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Figure 5. The increase in the glutamate efflux in response to 50 Hz stimulation was significantly related to
the interictal basal glutamate levels measured with zero-flow microdialysis at the stimulation site. (p =
0.001, n = 9, linear regression on log-transformed data).
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Dissociation Between Stimulus-Induced Glutamate Efflux and Stimulus-Induced Seizures
Stimulation of the epileptogenic hippocampus at 50 Hz triggered brief self-limited habitual
seizures in three cases and aura in two (Table 1). In one patient (patient #10), stimulation of the nonepileptogenic hippocampus also caused a brief habitual seizure. To investigate if the stimulus-induced
glutamate release was related to these triggered seizures, data from sites with seizures and with no seizures
were analyzed separately. Subjects without stimulus-induced seizure had a significant change in glutamate
efflux (F (16,98) = 2.38, p = 0.005, n = 7, Figure 6A) at the time of stimulation (p < 0.05, Tukey’s test).
Unexpectedly, there was no significant stimulus-induced glutamate efflux in subjects who experienced
seizure (F (16,61) = 1.00, p = 0.47, n = 4, Fig. 6A). Consistent with our earlier result (see Figure 5), basal
glutamate levels were significantly higher in the group that had stimulus-induced glutamate increase but no
seizures (8.8 ± 2.8 μM, n = 5, p = 0.04, t-test; Figure 6B) than in the group that had stimulated seizures but
no significant change in glutamate (2.4 ± 0.5 μM, n = 4). Thus, these data indicated that the elevation in
the interictal basal glutamate levels, but not the presence of seizures account for the increase in glutamate
in response to stimulation. Interestingly, the stimulus-induced seizures also occurred in the hippocampi
with relatively low – to - normal basal interictal glutamate levels.
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Figure 6. Stimulation of the hippocampus evoked self-limited seizures in four out of ten patients. A.
Significant glutamate efflux in response to stimulation (time 0 min) was observed in the group that did not
experience seizures (n = 7, p = 0.005, ANOVA), while glutamate levels did not change in the group that
had stimulated-seizures (n = 4, p = 0.47, ANOVA). B. The basal glutamate levels in the group that did not
experience seizures (n = 5) were significantly higher (p = 0.04, t-test on log transformed data) than in the
group that did experience stimulated seizures (n = 4).
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Discussion
This is the first study to report the effects of electrical stimulation on glutamate release in the
human hippocampus. Our subjects were awake patients who were undergoing intracranial EEG evaluation
of their seizure focus. Stimulation of the epileptogenic hippocampus at 50 Hz caused large, transient
glutamate efflux. In one case, where the non-epileptogenic hippocampus was stimulated, the stimulation
did not cause any change in the glutamate levels, but evoked a brief, self-limited seizure. Our studies
indicate that 50 Hz direct stimulation of the human hippocampus in patients with epilepsy can promote
excitability, instead of controlling it [123, 155-157], as five out of ten patients experienced seizures or
auras, despite being on their AEDs. However, in contrast to the spontaneous hippocampal seizures that are
known to be associated with large increases in glutamate [67, 77, 192], the stimulated-seizures were not
associated with significant glutamate efflux. Rather, the degree of stimulated glutamate increase was
related to the elevation in the interictal basal glutamate level. The factors that contribute to the elevation in
the interictal glutamate level in the human epileptogenic hippocampus are unknown. However, our study
indicates that elevated basal glutamate predispose to higher stimulus-induced increase, possibly by
affecting a shared mechanism of glutamate dysregulation.
Direct electrical stimulation of the hippocampus at 50 Hz was excitatory in six of ten patients; four
had short habitual, self-limited seizures and two patients reported auras. Seizures were induced with
stimulation of the epileptogenic as well as the non-epileptiogenic (in one case) hippocampus. This differs
from studies reporting that 50 Hz stimulation of the epileptogenic and non-epileptogenic cortex in
refractory epilepsy patients suppresses EEG spike rate and power, suggesting that this stimulation form has
an inhibitory effect on epileptiform activity [123, 155-158, 160-162]. Unfortunately, we have insufficient
EEG data to determine the effects of 50 Hz stimulation on EEG spike rate and power in this group of
patients. It is possible that the same stimulation frequency has different effects on excitability in the
hippocampus and in the cortex, and this remains to be studied.
Recent work on in vitro models of epilepsy may provide new insights as to the antiepileptic
mechanisms of 50 Hz stimulation in the hippocampus. Bikson et al. (2001) and Durand et al. (2006)
stimulated the CA1 region of the rat hippocampus at 50 Hz (sinusoidal) and observed that low-Ca2+,
picrotoxin, and high-K+ induced epileptiform activity was suppressed by potassium efflux and
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depolarization block [160].

Durand et al. (2006) expanded on these findings by citing that 50 Hz

stimulation of the alveus in the rat hippocampus suppressed spontaneous and evoked electrical activity in
the cell body and axons of surrounding neurons. In addition, Schiller and Bankirer (2007) found that 50 Hz
stimulation (biphasic square pulses lasting 0.2-0.4 ms) of rat neocortical slices treated with either
bicuculline or magnesium-free extracellular solution prematurely stopped ~50% of seizure-like events.
Interestingly, the additional use of ionotropic glutamate receptor blockers suppressed the epileptiform
discharges and enhanced the effects of 50 Hz stimulation, suggesting the possibility of short-term synaptic
depression of excitatory transmission following stimulation [162]. Thus, it is apparent that different trains
of stimulation (sinusoidal and square wave) could suppress epileptiform activity through different
mechanisms in vitro. This antiepileptic effect was not observed in vivo in the present study even though a
stimulation paradigm (50 Hz, biphasic square wave pulses, 0.2 ms per phase) similar to Schiller and
Bankirer’s (2007) was used. It is likely that the variability in response to stimulation may depend on other
complex factors, such as the underlying pathophysiology of the stimulated site, network connectivity and
recent history of the stimulated networks [132, 193].
Fifty Hz stimulation of the epileptogenic hippocampus also induced a large glutamate efflux at the
stimulated site. Although in most patients this glutamate increase was relatively brief, returning to baseline
within a couple of minutes, in few patients the glutamate levels remained elevated for up to 4-6 minutes
following stimulation. Unexpectedly, this marked increase in glutamate was not due to the evoked seizures,
as glutamate levels did not change significantly in the group that experienced seizures. Rather, the
stimulus-induced glutamate increase was positively correlated with the elevation in the interictal basal
glutamate concentration. We previously reported that the basal glutamate levels are abnormally high in the
epileptogenic hippocampus of patients with refractory MTLE,[82], and are associated with decreased
hippocampal volume [88] and neuronal cell count in the resected hippocampus [89]. Thus, the more
sclerotic the hippocampus, the worse the extracellular glutamate regulation is during the interictal state as
manifested by higher basal concentration and stimulated efflux. Whether the interictal accumulation of
extracellular glutamate is a consequence of impaired glutamate reuptake [86, 96, 194] increased neuronal
or glial release [83, 102, 195, 196] or slowed glial glutamate-glutamine metabolism in the human sclerotic
hippocampus [83, 98] remains unresolved.

However, the significant positive correlation between
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stimulated and interictal glutamate levels likely reflects a shared mechanism where stimulation at 50 Hz
exacerbates the already impaired glutamate regulation in the epileptogenic hippocampus.

Fifty Hz

stimulation did not, however, induce a significantly greater glutamate efflux in the sclerotic hippocampus
than in the unaffected side. We believe that this finding may have been due the limited subject number,
and in a larger study we would expect to find the glutamate surge following stimulation to be significantly
higher as well as stay elevated significantly longer in duration in the sclerotic hippocampi given the
aberrant glutamate handling of the affected site.
Our knowledge of how electrical stimulation affects neurotransmitter release is limited, and comes
mostly from animal studies [197]. Because of restrictions related to clinical care, we could not investigate
pharmacologically the mechanisms associated with stimulus-induced glutamate increase in our patients. In
addition, our electrode configuration and implant procedures preclude us from determining the precise site
of stimulation in the hippocampus. Since the distance between stimulated contacts is 13 mm, traversing the
cephalo-caudal axis of the hippocampus, we assume that most of the hippocampal subfields have been
stimulated. The increased glutamate release we observed may be due to impairment in one or several
mechanisms regulating neurotransmitter metabolism and release that would be best studied using in-vitro
preparations from human tissue or appropriate animal models.

Stimulation could induce neuronal

glutamate release that overwhelms an already impaired glial glutamate clearance mechanism, resulting in
extrasynaptic glutamate spillover [198] that can be detected by the microdialysis probes [181-183].
Electrical stimulation can also trigger glial glutamate release, either directly or through neuronal activation
[83, 98, 196, 199, 200], and may affect the glutamate – glutamine cycling, which is known to be impaired
in the epileptic hippocampus [83, 98]. On the other hand, studies in rat hippocampal slices of the CA1
region have demonstrated that 100 Hz square pulses can deplete extracellular calcium and subsequently
suppress presynaptic glutamate release [201].

Iremonger’s group used similar HFS at 125 Hz with

monophasic pulses to induce hippocampal LTD and decrease presynaptic glutamate release, as well as
decrease excitatory currents in rat motor cortex [178]. The frequency of stimulation is likely one of the
factors regulating neurotransmitter release.

For example, subthalamic stimulation in a rat model of

bradykinesia induced a frequency-dependent increase in microdialysate glutamate and GABA that reached
a plateau after 130 Hz, which incidentally is also the therapeutic stimulation frequency range (~50-350 Hz)
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for movement disorders [177]. Preliminary studies in epilepsy patients indicate that stimulation at 1 Hz
suppresses the abnormally elevated extracellular glutamate at epileptogenic brain sites [202]. Future
systematic studies will be needed to determine if stimulation methods that hold promise for seizure control
[30, 129, 153, 203, 204], such as very low or very high frequencies, are also associated with suppression of
glutamate release.
Spontaneous seizures in patients with intractable TLE are often associated with dramatic increases
in hippocampal extracellular glutamate [67, 77, 192]. In contrast, the stimulus-evoked seizures in our
patients did not cause significant change in glutamate levels. It is possible that spontaneous seizures are
associated with more widespread, extensive and prolonged impairment in neurotransmitter regulation or
metabolism, and therefore larger glutamate elevation. Alternatively, as suggested by our study, the degree
of basal glutamate dysregulation at the epileptic site could also determine the degree of glutamate increase
with seizures. Evidence for this is provided by studies in animals and in humans. Not all seizures are
associated with a glutamate increase. Naïve rats generally show little glutamate elevation in response to a
single acute electrical stimulation or administration of convulsants [67, 78, 79, 205, 206]. More reliable
increases in glutamate are observed in chronic animal models of epilepsy where there is more extensive
synaptic and cellular reorganization, such as kindling [67, 78, 79, 207] and with treatments that induce
cytoskeletal disruption [207, 208]. Wilson and colleagues (1996) observed that patients with hippocampal
sclerosis have a greater glutamate increase with seizures than patients with minimal hippocampal cell loss.
In our study, only one of four patients with evoked seizures had hippocampal atrophy, and the basal
glutamate levels in the seizure group were significantly lower, suggesting that the absence of glutamate
increase with evoked seizures is in part due to relatively intact glutamate regulation. Any small, transient
increases in glutamate may have been undetected by microdialysis, but may be measurable with more
sensitive neurochemical measures, such as glutamate sensors (Day et al., 2006). Then again, the induction
of seizures at sites of lower baseline extracellular glutamate – that are presumably more intact – is of
interest. In clinical practice, early efforts using stimulation to localize habitual seizures [209, 210] were
abandoned as seizures could be induced by the stimulation of non-affected sites. In addition, higher
glutamate levels might protect to some degree against seizure induction as elevation in the extrasynaptic
glutamate is reported to suppress the synaptic glutamate release by activation of the presynaptic
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metabotropic glutamate receptors [211, 212]. However this regulation is to some extent impaired in the
sclerotic hippocampus [211], where additional impairment in glutamate reuptake [93, 94], predisposing to
greater glutamate neurotoxicity.

Confounding Factors
Several factors limit the findings of the study. Methodological concerns include the technique of
intracerebral microdialysis used to estimate extracellular glutamate concentrations in the conscious human
hippocampus. It is important to note that microdialysis sampling reflects a pooled measure of extracellular
fluid in the immediate vicinity of the catheter. In the epileptogenic hippocampus, the amount of sclerosis
and atrophy may make it difficult to place the microdialysis probe directly in the most disease-affected
regions. For instance, the functionally and anatomically different anterior and posterior hippocampus may
be more involved in the patient’s epilepsy, and depending on probe placement, basal glutamate levels and
glutamate efflux following stimulation could vary. Since we did not do a sub-analysis on probe location
within the hippocampus due to the small number of patients under analysis, our confidence in describing
the extent of disease involvement in different hippocampal regions and how this relates to glutamate
concentrations in their proximity is limited. Nevertheless, microdialysis provides the closest in vivo look at
neurochemical activity of the epileptic human hippocampus. Another limitation to our findings is that we
may only conclude that 50 Hz stimulation induces glutamate efflux in the epileptogenic hippocampus. We
may not generalize to the non-epileptogenic hippocampus since only one non-epileptogenic hippocampus
was studied. Furthermore, we may not generalize our findings from the hippocampus to other regions of
the brain due to the great variation of neuronal architecture in different areas of the brain.

In our

experience, the changes in glutamate in response to 50 Hz stimulation of the epileptic cortex have been
more variable. Indeed, because the investigational procedure employed in this study involves an invasive
intracranial surgical procedure within a specific subset of patients with medically refractory epilepsy, there
is a limited number of patients available for study, even in a large epilepsy center over the course of 5
years.

The small patient size examined in this investigation may have prevented the emergence of

statistically significant results that would have been realized in a larger study, and may have resulted in
spurious results that would not be significant within a greater sample size. Lastly, since we do not have
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EEG data from the stimulated probes at the time of stimulation, we could not study the effects of 50 Hz
stimulation on interictal spiking (another surrogate marker for excitability) and relate these findings to
basal glutamate levels at the probe site, which may have allowed us to further support our findings.

Clinical Implications
Fifty Hz electrical brain stimulation is a candidate therapy for treatment of medically refractory
epilepsy. In general, neurostimulation offers the advantage over traditional AED treatment because it is
focal and offers the advantage over resective epilepsy surgery because it is reversible and modifiable.
Although preliminary evidence studying efficacy have been favorable, stimulation parameters have often
been chosen empirically or based on limited evidence from other disorders and from animal models, and
much remains unknown regarding optimal stimulation parameters fro seizure control. Furthermore, the
neurotoxicity and excitability associated with high basal glutamate levels within the epileptogenic
hippocampus underlie the importance of studying the effect of electrical brain stimulation on the brain’s
neurochemical environment. This study helps address this point by examining the effects of a candidate
frequency on the neurochemical environment of its target. Overall, such studies are necessary in order to
attain a greater understanding of how electrical brain stimulation affects the human brain. Such knowledge
could then help design more rationale strategies for brain stimulation and optimize the treatment of
medically refractory epilepsy.
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Conclusion
In summary, 50 Hz stimulation of the hippocampus in patients with medication-resistant TLE
resulted in significant increase in extracellular glutamate concentration and in seizures in some patients.
The magnitude of this glutamate increase was related not to the induction of seizures but to the elevation in
interictal baseline glutamate, suggesting that the extent of glutamate dysregulation at baseline determines
the degree of glutamate increase upon stimulation. This observation also suggests that shared mechanisms
underlie the elevation in glutamate under interictal conditions and with stimulation. Studies in animal
models indicate that repeated stimulations at sites where glutamate reuptake is impaired may lead to
progressive, gradual accumulation in extracellular glutamate [49, 140, 141, 213], and promote further
excitotoxicity and epileptogenicity. Therefore we conclude that stimulation of the epileptic hippocampus at
50 Hz may not be an optimal stimulation method for seizure control. Whether this stimulation method has
different effects in other brain sites, or other stimulation methods have different effects remains to be
studied.
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